Matches in Wikidata for { <http://www.wikidata.org/entity/Q90336238> ?p ?o ?g. }
Showing items 1 to 53 of
53
with 100 items per page.
- Q90336238 description "artículu científicu espublizáu en xineru de 2020" @default.
- Q90336238 description "scientific article published on 27 January 2020" @default.
- Q90336238 description "wetenschappelijk artikel" @default.
- Q90336238 description "наукова стаття, опублікована 27 січня 2020" @default.
- Q90336238 name "Phase II Trial of Carfilzomib Plus Irinotecan in Patients With Small-cell Lung Cancer Who Have Progressed on Prior Platinum-based Chemotherapy" @default.
- Q90336238 name "Phase II Trial of Carfilzomib Plus Irinotecan in Patients With Small-cell Lung Cancer Who Have Progressed on Prior Platinum-based Chemotherapy" @default.
- Q90336238 type Item @default.
- Q90336238 label "Phase II Trial of Carfilzomib Plus Irinotecan in Patients With Small-cell Lung Cancer Who Have Progressed on Prior Platinum-based Chemotherapy" @default.
- Q90336238 label "Phase II Trial of Carfilzomib Plus Irinotecan in Patients With Small-cell Lung Cancer Who Have Progressed on Prior Platinum-based Chemotherapy" @default.
- Q90336238 prefLabel "Phase II Trial of Carfilzomib Plus Irinotecan in Patients With Small-cell Lung Cancer Who Have Progressed on Prior Platinum-based Chemotherapy" @default.
- Q90336238 prefLabel "Phase II Trial of Carfilzomib Plus Irinotecan in Patients With Small-cell Lung Cancer Who Have Progressed on Prior Platinum-based Chemotherapy" @default.
- Q90336238 P1433 Q90336238-C57636C7-69E6-4EB6-A9FF-0F1740AE3FB2 @default.
- Q90336238 P1476 Q90336238-44EFE92A-CEE8-4410-8273-CB7D2056DBD5 @default.
- Q90336238 P2093 Q90336238-1727AABD-AF5C-4301-A53B-B7E7AE401EC7 @default.
- Q90336238 P2093 Q90336238-1F62FA76-8FCB-479C-935C-252C38CB85BE @default.
- Q90336238 P2093 Q90336238-38E41E19-F5CE-4A48-9C85-685FE7F25061 @default.
- Q90336238 P2093 Q90336238-3F2D65F3-574C-4D2D-8269-1BDE28A50CD1 @default.
- Q90336238 P2093 Q90336238-530B44E1-FB7C-4C54-80D9-42F2FFC35EBC @default.
- Q90336238 P2093 Q90336238-6C826A76-7E7B-4862-BC49-7284C6F66565 @default.
- Q90336238 P2093 Q90336238-9A08C0F9-88B7-4380-AFCB-1A76C31EF897 @default.
- Q90336238 P2093 Q90336238-A31D7E48-66AB-4B0A-85EB-2C222AF0CF43 @default.
- Q90336238 P2093 Q90336238-BAA74DC4-6EA6-4702-A1EA-267DC0FCD7C8 @default.
- Q90336238 P2093 Q90336238-C9201B03-AEA9-4B26-89AA-8DB486422C4C @default.
- Q90336238 P2093 Q90336238-CEF71066-1077-4545-A761-C7501BAD998F @default.
- Q90336238 P2093 Q90336238-F165C132-D089-441E-A0A0-5BC230549DD4 @default.
- Q90336238 P31 Q90336238-9301B9E5-36DB-422F-A6EA-62A405B1991F @default.
- Q90336238 P356 Q90336238-FC94856A-0858-4F7C-95A0-3D4FE8E8104B @default.
- Q90336238 P577 Q90336238-5658B48C-FFE1-469C-B0E4-568ECF6F6811 @default.
- Q90336238 P698 Q90336238-B06CF066-86E8-44BA-89FC-9E37E0430CAB @default.
- Q90336238 P921 Q90336238-07E36DBF-898D-4EB9-BC38-0A9FAAEBE809 @default.
- Q90336238 P921 Q90336238-99CF0C29-AA8A-4DEB-9E2A-4ED16F8BD77C @default.
- Q90336238 P356 J.CLLC.2020.01.006 @default.
- Q90336238 P698 32173247 @default.
- Q90336238 P1433 Q332299 @default.
- Q90336238 P1476 "Phase II Trial of Carfilzomib Plus Irinotecan in Patients With Small-cell Lung Cancer Who Have Progressed on Prior Platinum-based Chemotherapy" @default.
- Q90336238 P2093 "John Hamm" @default.
- Q90336238 P2093 "John J Crowley" @default.
- Q90336238 P2093 "John L Villano" @default.
- Q90336238 P2093 "Joseph Rosales" @default.
- Q90336238 P2093 "Kari Chansky" @default.
- Q90336238 P2093 "Maria Q Baggstrom" @default.
- Q90336238 P2093 "Markos Leggas" @default.
- Q90336238 P2093 "Maurice Willis" @default.
- Q90336238 P2093 "Michael A Thompson" @default.
- Q90336238 P2093 "Rachel E Sanborn" @default.
- Q90336238 P2093 "Saiama N Waqar" @default.
- Q90336238 P2093 "Susanne M Arnold" @default.
- Q90336238 P31 Q13442814 @default.
- Q90336238 P356 "10.1016/J.CLLC.2020.01.006" @default.
- Q90336238 P577 "2020-01-27T00:00:00Z" @default.
- Q90336238 P698 "32173247" @default.
- Q90336238 P921 Q412197 @default.
- Q90336238 P921 Q42824440 @default.